Better Therapeutics, Inc. (BTTX)

$1.3

-0.07 (-4.76%)
Rating:
Recommendation:
-
Symbol BTTX
Price $1.3
Beta 0.030
Volume Avg. 0.03M
Market Cap 30.868M
Shares () -
52 Week Range 0.912-5.1
1y Target Est -
DCF Unlevered BTTX DCF ->
DCF Levered BTTX LDCF ->
ROE -274.50% Strong Sell
ROA -217.52% Strong Sell
Operating Margin -
Debt / Equity 289.15% Strong Buy
P/E -
P/B 4.25 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest BTTX news


Healthcare
Biotechnology
NASDAQ Capital Market

Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. Its clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.